TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16405547

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 1115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1115

Group type: EXPERIMENTAL
Intervention: Minor papilla sphincterotomy
Number of subjects: 1115

Group type: EXPERIMENTAL
Intervention: Suspected sphincter of Oddi dysfunction (SOD)
Number of subjects: 1115

Group type: EXPERIMENTAL
Intervention: History of post-ERCP pancreatitis
Number of subjects: 1115

Group type: EXPERIMENTAL
Intervention: Age <60 years
Number of subjects: 1115

Group type: EXPERIMENTAL
Intervention: >=2 contrast injections into the pancreatic duct
Number of subjects: 1115

Group type: EXPERIMENTAL
Intervention: Trainee involvement
Number of subjects: 1115
Study: 15380456

Group type: EXPERIMENTAL
Intervention: Fluvastatin (40 mg daily)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg daily)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Ciprofibrate (100 mg daily)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg daily)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Healthy subjects (n = 59)
Number of subjects: 131
Study: 10734016

Group type: EXPERIMENTAL
Intervention: 4 microgram/kg IL-10 subcutaneously daily for 90 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 8 microgram/kg IL-10 subcutaneously daily for 90 days
Number of subjects: 24
Study: 8736999

Group type: EXPERIMENTAL
Intervention: Ethanol exposure in HR subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethanol exposure in C57BL/6 mice (analogous to HR human subjects)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of opioid receptor density in C57BL/6 mice and DBA/2 mice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of opioid receptor density in AA rats and ANA rats
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethanol exposure in ethanol-preferring animals
Number of subjects: 0
Study: 1551151

Group type: EXPERIMENTAL
Intervention: Patient-controlled lumbar epidural (PCA-E) fentanyl
Number of subjects: 34

Group type: COMPARATOR
Intervention: Patient-controlled intravenous (PCA-i.v.) fentanyl
Number of subjects: 34
Study: 3926511

Group type: EXPERIMENTAL
Intervention: Glucose infusions
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline infusions
Number of subjects: 12
Study: 31524303

Group type: EXPERIMENTAL
Intervention: Shame mood induction group
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study: 30700364

Group type: EXPERIMENTAL
Intervention: Posterior approach surgery
Number of subjects: 84

Group type: COMPARATOR
Intervention: Anterior approach surgery
Number of subjects: 84
Study: 29061618

Group type: EXPERIMENTAL
Intervention: Usual care plus additional in-bed cycling sessions
Number of subjects: 68

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 68
Study: 25740265

Group type: EXPERIMENTAL
Intervention: QMF149 150/80 μg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: QMF149 150/320 μg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both QMF149 doses
Number of subjects: 48
Study: 24967423

Group type: EXPERIMENTAL
Intervention: Levitan FPS optical stylet
Number of subjects: 79

Group type: COMPARATOR
Intervention: Lary-Flex videolaryngoscope
Number of subjects: 79
Study: 21849557

Group type: EXPERIMENTAL
Intervention: Corticospinal excitability assessed using single-pulse transcranial magnetic stimulation (TMS) over the upper-arm region of M1 (primary motor cortex) during movements with resistive interaction torques.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Corticospinal excitability assessed using single-pulse transcranial magnetic stimulation (TMS) over the upper-arm region of M1 (primary motor cortex) during movements with assistive interaction torques.
Number of subjects: 12
Study: 19138537

Group type: EXPERIMENTAL
Intervention: Automated measurement of joint space width (JSW) using a novel software program
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Automated measurement of joint space narrowing (JSN) using a novel software program
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sensitivity to change of JSW
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Observer intervention for computer measurement
Number of subjects: 50
Study: 17472415

Group type: EXPERIMENTAL
Intervention: Ruboxistaurin
Number of subjects: 685

Group type: EXPERIMENTAL
Intervention: Ruboxistaurin at a dose of 32 mg/day
Number of subjects: 685
Study: 15451153

Group type: EXPERIMENTAL
Intervention: Pacemaker ON
Number of subjects: 29
Study: 11361052

Group type: EXPERIMENTAL
Intervention: Linezolid (625 mg bid orally)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Moclobemide (150 mg tid orally)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Linezolid and Moclobemide
Number of subjects: 31
Study: 10345150

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (EGb 761) 80 mg twice daily
Number of subjects: 44

Group type: COMPARATOR
Intervention: Betahistine dihydrochloride (BI) 16 mg twice daily
Number of subjects: 44
Study: 7537666

Group type: EXPERIMENTAL
Intervention: Metastron (strontium‐89 chloride)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 2497633

Group type: EXPERIMENTAL
Intervention: Fresh yogurt ingestion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Heated yogurt ingestion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: In vitro yogurt at pH 5.0
Number of subjects: 10
Study: 31418811

Group type: EXPERIMENTAL
Intervention: Walk On! (WO) intervention
Number of subjects: 2707

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 2707
Study: 29086490

Group type: EXPERIMENTAL
Intervention: Intervention (watching video lessons at home plus peer support group teleconferences)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 338
Study: 25311914

Group type: EXPERIMENTAL
Intervention: GnRH treatment (100 µg)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Saline treatment
Number of subjects: 33
Study: 23108952

Group type: EXPERIMENTAL
Intervention: ECX (Epirubicin, Cisplatin, Capecitabine)
Number of subjects: 200

Group type: COMPARATOR
Intervention: ECX-B (ECX with Bevacizumab)
Number of subjects: 200
Study: 21614665

Group type: COMPARATOR
Intervention: Control group (28 participants)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Standard training group (26 participants)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Overtraining group (23 participants)
Number of subjects: 98
Study: 19711607

Group type: EXPERIMENTAL
Intervention: Daily use of 6% hydrogen peroxide/pyrophosphate whitening strips for five minutes on the facial and lingual surfaces of the mandibular teeth.
Number of subjects: 77

Group type: COMPARATOR
Intervention: Regular brushing (brushing control).
Number of subjects: 77
Study: 16925613

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: H. pylori eradication
Number of subjects: 0

Group type: COMPARATOR
Intervention: H. pylori treatment
Number of subjects: 0
Study: 15370776

Group type: EXPERIMENTAL
Intervention: Reasons For Living inventory (RFL)
Number of subjects: 506
Study: 11253839

Group type: EXPERIMENTAL
Intervention: High-dose zidovudine (AZT) 1500 mg/day
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 9250555

Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8055497

Group type: EXPERIMENTAL
Intervention: Electric toothbrush
Number of subjects: 32

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 32
Study: 2883680

Group type: EXPERIMENTAL
Intervention: Zotepine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thiothixene
Number of subjects: 0
Study: 30192260

Group type: EXPERIMENTAL
Intervention: Falls incident reports analysis
Number of subjects: 493
Study: 31533069

Group type: EXPERIMENTAL
Intervention: Alirocumab (150 mg every 2 weeks or 75 mg every 2 weeks with possible increase to 150 mg at 12 weeks)
Number of subjects: 4975

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 4975

Group type: COMPARATOR
Intervention: Placebo/Ezetimibe (control)
Number of subjects: 4975
Study: 28407338

Group type: EXPERIMENTAL
Intervention: Tolterodine ER 4 mg once daily for 12 weeks
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo once daily for 12 weeks
Number of subjects: 79
Study: 27647480

Group type: EXPERIMENTAL
Intervention: Repaglinide added to sitagliptin (ADD-ON, n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sitagliptin switched to repaglinide (SWITCH, n=20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Repaglinide added to sitagliptin (ADD-ON)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination therapy (ADD-ON)
Number of subjects: 40
Study: 24368638

Group type: EXPERIMENTAL
Intervention: Extended resection
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard resection
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiation
Number of subjects: 200
Study: 23377513

Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate 1.2% and tretinoin 0.025% gel
Number of subjects: 42

Group type: COMPARATOR
Intervention: Clindamycin gel (1% clindamycin phosphate)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Combination gel (clindamycin phosphate 1.2% and tretinoin 0.025%)
Number of subjects: 42
Study: 20650919

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg kg(‐1) bolus then 2 mg kg(‐1) h(‐1) infusion)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (0.75 mg kg(‐1) bolus then infusion 1 mg kg(‐1) h(‐1))
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (1.5 mg kg(‐1) bolus and infusion 2 mg kg(‐1) h(‐1))
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (3 mg kg(‐1) bolus and infusion 4 mg kg(‐1) h(‐1))
Number of subjects: 40
Study: 18772216

Group type: EXPERIMENTAL
Intervention: i.v. midazolam 0.02 mg kg(‐1)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: i.v. midazolam 0.06 mg kg(‐1)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 45
Study: 15812375

Group type: EXPERIMENTAL
Intervention: Abnormal QRS score
Number of subjects: 128

Group type: COMPARATOR
Intervention: ST-segment deviation
Number of subjects: 128
Study: 12088299

Group type: EXPERIMENTAL
Intervention: Surgery alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of surgery and radiation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant therapy based on pathologic risk factors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irradiation in recurrent endometrial cancer after surgery alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Palliative radiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ongoing prospective randomized trials
Number of subjects: 0
Study: 11037367

Group type: EXPERIMENTAL
Intervention: Group-based cognitive-behavioural therapy (CBT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 20
Study: 8675164

Group type: EXPERIMENTAL
Intervention: Hepatic vascular exclusion (HVE)
Number of subjects: 15
Study: 1676306

Group type: EXPERIMENTAL
Intervention: Indomethacin (75 mg b.d.)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 6357207

Group type: EXPERIMENTAL
Intervention: Suprofen 100 mg + APAP 650 mg
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Suprofen 400 mg + APAP 650 mg
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Suprofen 200 mg
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 31269506

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA, 3.0 g/day)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Combination of EPA (1.5 g/day) and DHA (0.7 g/day)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Docosahexaenoic acid (DHA, 1.4 g/day)
Number of subjects: 88
Study: 28735832

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 19
Study: 26677770

Group type: EXPERIMENTAL
Intervention: RECODE COPD management programme, implementation measured with PACIC and ACIC scales.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: RECODE COPD management programme, implementation measured with own scale and ACIC.
Number of subjects: 20
Study: 22526572

Group type: EXPERIMENTAL
Intervention: Acellular dermal (alloderm) grafts
Number of subjects: 24

Group type: COMPARATOR
Intervention: Silastic sheets implants
Number of subjects: 24
Study: 22073579

Group type: EXPERIMENTAL
Intervention: Combination of long acting beta2 agonist (LABA) and inhaled corticosteroids (ICS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tiotropium alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbocisteine (mucolytic and anti-oxidant agent)
Number of subjects: 0
Study: 19253069

Group type: EXPERIMENTAL
Intervention: Computer-based memory training intervention, involving teaching and practicing two memory strategies over three training sessions.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting-list control group, no intervention provided.
Number of subjects: 0
Study: 17006377

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Tibolone 1.25 mg
Number of subjects: 396
Study: 11908552

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (Neoral-Sandimmun, 3 mg/kg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10839074

Group type: EXPERIMENTAL
Intervention: Paracetamol (30 to 50 mg/kg loading dose, followed by 70 to 100 mg/kg/24 hours)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Paracetamol (30 to 50 mg/kg loading dose, followed by 70 to 100 mg/kg/24 hours) plus intramuscular fentanyl citrate (1 microgram/kg)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Systematic pain assessments by nurses
Number of subjects: 83
Study: 8567509

Group type: EXPERIMENTAL
Intervention: 8% galactose solution with [1‐13C]galactose tracer
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 8% glucose solution with [U‐13C]glucose tracer
Number of subjects: 8
Study: 2138049

Group type: EXPERIMENTAL
Intervention: Cilazapril (1.25 to 5.0 mg/day, single dose)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 106432

Group type: EXPERIMENTAL
Intervention: 100 mg atenolol
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 80 mg propranolol
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 6138066

Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Midazolam 7.5 mg
Number of subjects: 47

Group type: COMPARATOR
Intervention: Oxazepam 25 mg
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Midazolam (various doses)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Midazolam (higher doses)
Number of subjects: 47
Study: 30596910

Group type: EXPERIMENTAL
Intervention: Nitroglycerine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triptan treatment (sumatriptan)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study: 29464748

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fluoroscopy guidance
Number of subjects: 40
Study: 27255243

Group type: EXPERIMENTAL
Intervention: New optical biometer (AL‐Scan)
Number of subjects: 121
Study: 25238912

Group type: EXPERIMENTAL
Intervention: Nut group (30 g/d of mixed nuts for 6 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 22348309

Group type: EXPERIMENTAL
Intervention: AeroEclipse II breath‐activated nebulizer (BAN)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Continuous flow small‐volume nebulizer (SVN)
Number of subjects: 40
Study: 20561643

Group type: EXPERIMENTAL
Intervention: Parasacral transcutaneous electrical nerve stimulation (20 sessions, 20 minutes each, 10 Hz)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Parasacral transcutaneous electrical nerve stimulation
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sham (superficial scapular electrical stimulation)
Number of subjects: 37
Study: 17902041

Group type: EXPERIMENTAL
Intervention: Psychoeducation
Number of subjects: 15
Study: 16521417

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg/day
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 11774098

Group type: EXPERIMENTAL
Intervention: Immunosuppressive therapy with prednisone and cyclophosphamide (n = 18)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Plasmapheresis in addition to immunosuppression (n = 21)
Number of subjects: 39
Study: 10610077

Group type: EXPERIMENTAL
Intervention: Regular moderate intensity physical activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diet rich in omega-3 fatty acids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical training or low fat diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regular physical activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 0
Study: 9150995

Group type: EXPERIMENTAL
Intervention: Subcutaneous injections of hot-spring gas for 15 days
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Prazosin VUFB for 28 days
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (Agapurin SPOFA) for 28 days
Number of subjects: 63
Study: 1837974

Group type: EXPERIMENTAL
Intervention: Depo‐Provera
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: Nur‐Isterate
Number of subjects: 653

Group type: COMPARATOR
Intervention: Injectables (Depo‐Provera and Nur‐Isterate)
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: Anti‐inflammatory and anti‐fibrinolytic agents
Number of subjects: 653
Study: 7347353

Group type: EXPERIMENTAL
Intervention: Upper gastrointestinal endoscopy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Upper gastrointestinal radiography
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Informed endoscopist
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Uninformed endoscopist
Number of subjects: 100
Study: 30994197

Group type: EXPERIMENTAL
Intervention: Test (soft contact lens with positive spherical aberration, +SA)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control (single-vision soft contact lens)
Number of subjects: 109
Study: 27116084

Group type: EXPERIMENTAL
Intervention: Audiovisual distraction (familiar folk music and images of nature) during FB
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care during FB (Control group)
Number of subjects: 60
Study: 26833219

Group type: EXPERIMENTAL
Intervention: Sham Streitberger's needle, Real Streitberger's needle, Phantom acupuncture session
Number of subjects: 76

Group type: COMPARATOR
Intervention: Park Sham device with real needle, Park Sham device with sham needle, no treatment session
Number of subjects: 76
Study: 24889893

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri tablets (DSM 17938 and ATCC PTA 5289), 2 tablets daily for 3 months
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo tablets without live bacteria
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study: 22518014

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV (type 6/11/16/18) virus-like particle vaccine
Number of subjects: 3819
Study: 19176423

Group type: EXPERIMENTAL
Intervention: QI-therapy
Number of subjects: 805

Group type: EXPERIMENTAL
Intervention: QI-meds
Number of subjects: 805

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 805
Study: 17161552

Group type: EXPERIMENTAL
Intervention: Endorectal balloon (ERB)
Number of subjects: 48

Group type: COMPARATOR
Intervention: No endorectal balloon (No-ERB)
Number of subjects: 48
Study: 16356431

Group type: EXPERIMENTAL
Intervention: Extra fluids (intravenous fluid supplementation for 8 hours and oral supplementation for the duration of phototherapy)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Extra fluids
Number of subjects: 74
Study: 12189481

Group type: EXPERIMENTAL
Intervention: endoscopic pulse detector
Number of subjects: 40
Study: 9449498

Group type: EXPERIMENTAL
Intervention: Subcutaneous epinephrine (0.01 ml/kg, maximum 0.3 ml [0.3 mg])
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Intramuscular epinephrine (0.3 mg from an autoinjector)
Number of subjects: 17
Study: 10150837

Group type: EXPERIMENTAL
Intervention: Antimetabolites as pharmacologic modulators of wound healing in conjunction with argon laser suture lysis and small‐incision phacoemulsification techniques
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current trends in the management of coincident glaucoma and cataract
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Role of antimetabolites in combined glaucoma surgery
Number of subjects: 0
Study: 2212181

Group type: EXPERIMENTAL
Intervention: Prevention program with formal provider training and implementation feedback
Number of subjects: 4466

Group type: EXPERIMENTAL
Intervention: Prevention program with videotaped provider training and no feedback
Number of subjects: 4466

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 4466

Group type: EXPERIMENTAL
Intervention: Prevention program (all types)
Number of subjects: 4466
Study: 619949

Group type: EXPERIMENTAL
Intervention: Aluminium hydroxide
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Glycopyrrhonium
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Aluminium hydroxide and glycopyrrhonium (combination)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ethanol (0.5 g/kg in 10% solution or 0.8 g/kg in 20% solution)
Number of subjects: 25
Study: 30259764

Group type: EXPERIMENTAL
Intervention: Insulin-treated diabetes
Number of subjects: 28771

Group type: EXPERIMENTAL
Intervention: Non-insulin-treated diabetes
Number of subjects: 28771

Group type: COMPARATOR
Intervention: No diabetes
Number of subjects: 28771
Study: 26826263

Group type: EXPERIMENTAL
Intervention: Diabetes-specific formula (DSF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard formula (SF)
Number of subjects: 0
Study: 26268772

Group type: EXPERIMENTAL
Intervention: Toothpaste containing 5% NovaMin and fluoride (ReNew™)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Over-the-counter fluoride toothpaste (Crest®)
Number of subjects: 48